CompletedInterventionalPhase 4Last updated Feb 8, 2023

The Effect of Effervescent Alendronate on Bone Turnover

The Effect of Effervescent and Buffered Alendronate on Bone Turnover Compared to Conventional Alendronate: A Randomized Non-inferiority Study

Overview

ClinicalTrials.gov ID: NCT05325515
Lead Sponsor: Aarhus University HospitalOTHER
Brief Summary: 64 postmenopausal women are randomized to treatment with either effervescent and buffered alendronate or conventional alendronate -both 70mg weekly for 16 weeks to see if bone turnover is suppressed to the same extent as in the conventional formulation with the effervescent form.
Study Type

Status

Overall Status: Completed
Start Date: Oct 1, 2021Actual
Primary Completion Date: Sep 1, 2022Actual
Completion Date: Dec 1, 2022Actual

Study Record Dates

First Submitted: Apr 5, 2022
First Submitted that Met QC Criteria: Apr 12, 2022
First Posted: Apr 13, 2022Actual
Last Update Submitted that Met QC Criteria: Feb 4, 2023
Last Update Posted: Feb 8, 2023Actual
Last Verified: Feb 2023

NCT03435094Unknown status

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

NCT04403698Completed

The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover

NCT00504166Completed

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

NCT00463268Completed

Osteoporosis Prevention With Low Dose Alendronate

NCT00398606Completed

A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)

NCT00641771Completed

4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)